Transplant Rejection

Question 1

Onset of Hyperacute

Answer 1

Within Minutes

Question 2

Antibody Mediated (type II) Pathogenesis because of presence of preformed anti-donor antibodies in the transplant recipient.

Answer 2

Hyperacute

Question 3

Features: Irreversible. T-cell and antibody-mediated vascular damage (obliterative vascular fibrosis); fibrosis of graft tissue and blood vessels

Answer 3

Chronic

Question 4

Onset of Graft-versus-Host

Answer 4

Varies

Question 5

Features: Occludes graft vessels, causing ischemia and necrosis usually due to different blood types.

Answer 5

Hyperacute

Question 6

Class I-MHC (nonself) is perceived by CTLs as class I-MHC (self) presenting a non-self antigen.

Answer 6

Chronic

Question 7

Cell-mediated due to CTLs reacting against foreign MHCs. Reversible with immunosuppressants.

Answer 7

Acute

Question 8

Features: Maculopapular rash, jaundice, hepatosplenomegaly, and diarrhea.

Answer 8

Graft-versus-Host

Question 9

Features: Vasculitis of graft vessels with dense interstitial lymphocytic infiltrate.

Answer 9

Acute

Question 10

Onset of Chronic

Answer 10

Months to Years

Question 11

Grafted immunocompetent T cells proliferate in the irradiated immunocompromised disease host and reject cells within “foreign” proteins, resulting in severe organ dysfunction.

Answer 11

Graft-versus-Host

Question 12

Features: Usually in bone marrow and liver transplant (organs rich in lymphocytes). Potentially beneficial in bone marrow.

Answer 12

Graft-Versus-Host

Question 13

Onset of Acute

Answer 13

Weeks (1-4 weeks) later